Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.

By P. Hansson, J. Sörbo, H. Eriksson. Archives of Internal Medicine, 2000

637 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Epidemiology of cancer-associated venous thrombosis. (2013, background): “[66-68] Cancer patients are at an approximately two to three-fold increased risk of recurrent venous thrombosis compared with non-cancer patients.”
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “5-fold) than after a first unprovoked event.(57,58) For the decision about whether to stop treatment at 3 months or to treat indefinitely (“extended treatment”), we categorized a”
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. (2020, background): “This risk has been estimated to be as high as 10% by 1 year and up to 30% by 5 to 10 years.(10,11,313) The ASH guideline panel has provided a conditional recommendation for continuing antithrombotic therapy indefinitely after completion of primary treatment for patients with unprovoked VTE, based on”
Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study (2005, neutral): “Postthrombotic syndrome, n (%) 46 (23) 48 (24)”
Thrombophilia, clinical factors, and recurrent venous thrombotic events. (2005, neutral): “Incidence rate (95% CI)† 29 (13-58) 44 (32-58) 15 (10-24) 17 (9-29)”